Director of the First Department of Thoracic Oncology, Chief Physician/Professor Specializes in thoracic tumors, particularly in the clinical diagnosis, treatment, and scientific research of lung cancer, pleural mesothelioma, and thymic tumors, with a systematic approach and framework. Focuses on MDT (Multidisciplinary Team) diagnostic and treatment models, emphasizing individualized comprehensive therapy, with special attention to elderly lung cancer patients, balancing treatment safety and survival benefits to develop personalized regimens for elderly patients. Translational research focuses on the tumor microenvironment, innovatively proposing the "microbe-tumor metabolic coupling" theory, systematically revealing the mechanism by which lung adenocarcinoma-associated microbiota activate the HIF-1α pathway via the lactate-MCT1 axis, providing new insights for targeting the microenvironment. As a member of the expert panel for the "CSCO Guidelines for the Diagnosis and Treatment of Non-Small Cell Lung Cancer" and Deputy Editor-in-Chief of the "CACA Guidelines for the Protection of Elderly Lung Cancer Patients," has participated in the development of multiple industry standards. Authored "Comprehensive Geriatric Oncology for Lung Cancer," which has become an important reference in the field. Current academic positions include President of the Oncology Branch of the China Ethnic Medicine Association, Honorary Chair of the Committee of Chemotherapy for Cancer of the China Medical Education Association, and Vice Chair of the Geriatric Oncology Committee of the Chinese Gerontology and Geriatrics Society. Publications: · Lactate production by tumor-resident Staphylococcus promotes metastatic colonization in lung adenocarcinoma. Cell Host & Microbe. 2025; 33, 1089–1105. · Prognostic significance of micropapillary pattern and risk factors in patients with resected stage I lung adenocarcinoma and possible benefit of adjuvant therapy: a real-world multicenter study. Transl Lung Cancer Res 2025; 14(7):2760-2770. · Secreted proteins MDK, WFDC2, and CXCL14 as candidate biomarkers for early diagnosis of lung adenocarcinoma. BMC Cancer. 2023; 23:110. · Significant Upregulation of HERV-K (HML-2) Transcription Levels in Human Lung Cancer and Cancer Cells. Frontiers in Microbiology. March 2022 | Volume 13 | Article 850444. · Identification of serum biomarkers to predict pemetrexed/platinum chemotherapy efficacy for advanced lung adenocarcinoma patients by data-independent acquisition (DIA) mass spectrometry analysis with parallel reaction monitoring (PRM) verification. Transl Lung Cancer Res 2021;10(2):981-994.